PRTA - Prothena GAAP EPS of -$0.71 revenue of $1.17M
Prothena press release (NASDAQ:PRTA): Q4 GAAP EPS of -$0.71. Revenue of $1.17M (+225.0% Y/Y). FY 2022 Guidance: The company expects the full year 2022 net cash used in operating and investing activities to be $120 to $132 million, which includes an expected $40 million clinical milestone payment from Novo Nordisk, and expects to end the year with approximately $454 million in cash, cash equivalents and restricted cash (midpoint). The estimated full year 2022 net cash used in operating and investing activities is primarily driven by an estimated net loss of $154 to $170 million, which includes an estimated $32 million of non-cash share-based compensation expense.
For further details see:
Prothena GAAP EPS of -$0.71, revenue of $1.17M